Optimization of the Patient Care Pathway in Immuno-oncology

Inclusion criteria

• Patient with advanced (unresectable melanoma (stage III)) or metastatic (stage IV) melanoma and starting an Immune Checkpoint Inhibitor treatment (Monotherapy or Combination Therapy)
• Patient starting first cycle of Immune Checkpoint Inhibitor treatment in an ambulatory care structure
• Treatment which can be delayed for 7 days or more
• Age > or = 18 years old
• Patient with a phone and/or computer equipment
• Patient affiliated to the french social security system
• Patient must provide written informed consent prior to any study-specific procedure or assessment

Exclusion criteria

• Patient with diagnosis other than advanced melanoma
• Patient who must receive a treatment other than Immune Checkpoint Inhibitor
• Treatment administered during a conventional hospital stay (period of more than 24 hours)
• Patient with no caregiver
• Pregnant or breastfeeding women
• Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure
• Patient protected by law